XSTOBIOAb
Market cap1.70bUSD
Dec 23, Last price
202.00SEK
1D
-5.08%
1Q
25.47%
IPO
587.07%
Name
BioArctic AB
Chart & Performance
P/E
81.74
P/S
30.42
EPS
2.47
Div Yield, %
0.00%
Shrs. gr., 5y
0.10%
Rev. gr., 5y
-2.91%
Revenues
616m
+169.83%
Net income
229m
P
CFO
310m
P
Dividend
May 10, 20191.5 SEK/sh
Earnings
Feb 13, 2025
Profile
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 615,995 169.83% | 228,291 886.31% | 23,146 -62.88% | ||||||
Cost of revenue | 89,627 | 148,652 | 134,986 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 526,368 | 79,639 | (111,840) | ||||||
NOPBT Margin | 85.45% | 34.88% | |||||||
Operating Taxes | 47,237 | 11 | (20,723) | ||||||
Tax Rate | 8.97% | 0.01% | |||||||
NOPAT | 479,131 | 79,628 | (91,117) | ||||||
Net income | 229,249 -2,150.89% | (11,178) -90.67% | (119,789) 74.83% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 14,982 | 5,985 | |||||||
BB yield | -0.06% | -0.02% | |||||||
| Debt | |||||||||
Debt current | 2,827 | 8,857 | 8,092 | ||||||
Long-term debt | 7,131 | 11,221 | 23,662 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,000 | ||||||||
Net debt | (1,103,256) | (786,914) | (818,239) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 309,694 | (31,638) | (140,457) | ||||||
CAPEX | (7,443) | (12,746) | (4,386) | ||||||
Cash from investing activities | (507,485) | (12,763) | (4,412) | ||||||
Cash from financing activities | 14,064 | (2,808) | (7,389) | ||||||
FCF | 483,269 | 78,111 | (84,925) | ||||||
| Balance | |||||||||
Cash | 1,111,567 | 805,386 | 848,405 | ||||||
Long term investments | 1,647 | 1,606 | 1,588 | ||||||
Excess cash | 1,082,414 | 795,577 | 848,836 | ||||||
Stockholders' equity | 465,596 | 220,241 | 228,658 | ||||||
Invested Capital | 585,958 | 576,040 | 575,896 | ||||||
ROIC | 82.47% | 13.83% | |||||||
ROCE | 49.47% | 10.00% | |||||||
| EV | |||||||||
Common stock shares outstanding | 88,487 | 88,074 | 88,060 | ||||||
Price | 267.80 -1.54% | 272.00 128.19% | 119.20 24.95% | ||||||
Market cap | 23,696,926 -1.08% | 23,956,210 128.23% | 10,496,750 24.95% | ||||||
EV | 22,593,670 | 23,169,296 | 9,678,511 | ||||||
EBITDA | 544,796 | 93,823 | (98,795) | ||||||
EV/EBITDA | 41.47 | 246.95 | |||||||
Interest | 379 | 559 | 838 | ||||||
Interest/NOPBT | 0.07% | 0.70% | |||||||